In The News Archivi

Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma

In The News

At IRBM we are passionate about helping companies develop medicines in a wide range of diseases and our scientists support the fundamental understanding of disease mechanisms. Science is about collaboration, and publication is an integral part of the scientific process.

IRBM & collaborators publish on techniques for characterizing peptides in Type 2 diabetes and a peptide drug discovery program for Huntington’s disease

In The News, Scientific Contributions

Nowadays, there is a strong drive to explore new areas of chemical space in search of innovative ways to bind and modulate challenging biological targets. At IRBM our peptide chemistry team has extensive expertise in peptide and macrocyclic drug discovery in various therapeutic areas.

Covid, a young international team: that’s how Pomezia works on the vaccine

In The News, in The News, Press Review

In an 80,000 m2 site 20 miles from Rome, young researchers from around the world work day and night making history. They have played a key role in the development of the Covid-19 vaccine, after the Jenner Institute (expert in…

IRBM to collaborate with MSD to develop peptides against coronavirus

In The News, Press Releases

Builds on Research to Combat Severe Acute Respiratory Syndrome (SARS)
Rome, Italy – IRBM, a global Contract Research Organization today announced a new research collaboration agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) to identify and develop novel peptide therapeutics active against different strains of coronavirus, including SARS-CoV-2.

IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford

In The News, Press Releases

Pomezia, Italy - Advent Srl, an IRBM company and global leader in viral vector manufacturing, announces it has manufactured 13,000 doses of the novel Covid-19 vaccine candidate, ChAdOx1 nCoV-19.

In Memory of Maurizio Botta: His Vision of Medicinal Chemistry

In The News

IRBM’s medicinal chemists are incredibly proud to have contributed 3 articles to a special issue of the ACS Medicinal Chemistry Letters in memory of Professor Maurizio Botta. Many of our chemistry team were former students of the professor and are therefore thrilled to be part of this tribute.

IRBM supporting the effort to cope with the impact of coronavirus

In The News

There are many ways to face the impact of coronavirus. Due to the worldwide pandemic, there is a blood shortage in several hospitals. The staff at IRBM set up, in partnership with Ema-Roma, a Blood Donation Day. This highly worthwhile…

IRBM’s Chief Science Officer, Carlo Toniatti is featured in the Medicine Maker’s Power List

In The News, Scientific Contributions

Carlo joins other leading authorities in drug discovery and development as part of the Biopharmaceuticals category in the Medicine Maker Power List. In his interview he reviews future trends in drug development and some of the defining moments of his…

BBC came to film IRBM’s Advent GMP facility

In The News

Recently the BBC came to film IRBM’s Advent GMP facility and interview our Managing Director, Matteo Liguori about the manufacture of the Covid-19 vaccine...

Targeting The HIV-1 Nucleocapsid Protein To Fight Antiretroviral Drug Resistance

Dihydroxypyrimidine Scaffold to Target HIV‑1 Nucleocapsid Protein

In The News, Scientific Contributions

IRBM and their collaborators’ at the universities of Strasbourg and Siena have recently published a paper in the ACS Medicinal Chemistry Letters which describes their approach to the identification of a 5-dihydroxypyrimidine-6-carboxamide substructure as a privileged scaffold of a new…